HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Arbutus Biopharma (NASDAQ:ABUS) and maintained a price target of $5.
June 06, 2024 | 10:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Arbutus Biopharma and maintained a price target of $5, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price of Arbutus Biopharma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100